Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 06:28pm CEST
   By Peter Loftus 
   Of  
 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
02:46p ABBOTT LABORATORIES : Today's Research Reports on Stocks to Watch: Abbott Labora..
07/20 PPG and C.H. Robinson slip while Abbott and Sears advance
07/20 Abbott profit forecast gets a lift from St. Jude integration
07/20 ABBOTT LABORATORIES (NYSE : ABT) reported earnings of $0.62 per share beating Wa..
07/20 ABBOTT LABORATORIES : revenue grows 4.4 percent, but pacemaker sales drop
07/20 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Results of Operations and Financia..
07/20 ABBOTT LABORATORIES : tops Street 2Q forecasts
07/20 ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
07/20 ABBOTT : Reports Second-Quarter 2017 Results
07/17ABBOTT LABORATORIES : half-yearly earnings release
More news
News from SeekingAlpha
07:04a WALL STREET BREAKFAST : Confidence In Bitcoin Is Back
07/20 Quidel To Acquire Triage Assets From Alere Divestiture
07/20 Abbott's (ABT) CEO Miles White on Q2 2017 Results - Earnings Call Transcript
07/20 Abbott Laboratories Q2 revenues up 25%; non-GAAP EPS up 13%; updates guidance
07/20 Abbott Laboratories beats by $0.01, beats on revenue
Financials ($)
Sales 2017 26 496 M
EBIT 2017 5 730 M
Net income 2017 2 854 M
Debt 2017 15 409 M
Yield 2017 2,12%
P/E ratio 2017 34,83
P/E ratio 2018 25,52
EV / Sales 2017 3,91x
EV / Sales 2018 3,63x
Capitalization 88 239 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 52,9 $
Spread / Average Target 4,0%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES32.39%88 239
JOHNSON & JOHNSON17.36%367 897
NOVARTIS9.58%222 704
ROCHE HOLDING LTD.4.94%222 036
PFIZER3.26%199 735
MERCK AND COMPANY6.91%172 151